Collin Blakely MD, PhD, associate professor of medicine, University of California, San Francisco (UCSF), medical oncologist, UCSF Health, discusses the design of an ongoing phase 2 trial (NCT03433469) examining osimertinib (Tagrisso) in resectable 

-mutant non–small cell lung cancer (NSCLC).

The non-randomized, multi-institution trial screened patients with stage I to IIIA NSCLC, Blakely explains. Patients who have 

 mutation or an exon 19 deletion, were eligible for enrollment, Blakely adds. Patients who met all screening criteria received 1 to 2 months of neoadjuvant osimertinib, followed by standard surgical resection, Blakely says.

The tissue was analyzed for major pathological response and patients were continuously followed after surgery to examine disease-free and overall survival, Blakely continued. In the adjuvant setting, patients could receive physician’s choice of standard therapy, such as chemotherapy or osimertinib, Blakely concludes.

Videos

Collin Blakely MD, PhD, discusses the design of an ongoing phase 2 trial examining osimertinib in resectable EGFR-mutant non–small cell lung cancer.

Dr. Blakely on the Design of a Trial Evaluating Osimertinib in Resectable EGFR-Mutant NSCLC 

Collin Blakely MD, PhD, associate professor of medicine, University of California, San Francisco (UCSF), medical oncologist, UCSF Health, discusses the rationale for utilizing osimertinib (Tagrisso) in resectable 

 mutations in NSCLC is an effective way to induce tumor shrinkage, Blakely says. Moreover, adjuvant osimertinib has been shown to extend disease-free survival in patients with 

-mutated disease. However, it is not known whether it is possible to utilize osimertinib in the neoadjuvant setting and obtain the same degree of tumor reduction and pathological response as in the adjuvant setting, Blakely explains.

Pathological response has been shown to correlate with overall survival; this concept served as the basis to evaluate neoadjuvant osimertinib in patients with early-stage NSCLC, Blakely concludes.

Collin Blakely MD, PhD, discusses the rationale for utilizing osimertinib in resectable EGFR-mutant non–small cell lung cancer.

Collin Blakely MD, PhD

Articles

Dr. Blakely on the Design of a Trial Evaluating Osimertinib in Resectable EGFR-Mutant NSCLC

Dr. Blakely on Utilizing Osimertinib in Resectable EGFR-Mutant NSCLC